ICMJE DISCLOSURE FORM

Date:	2/21/2023
Your Name:	Louise E Duvall
Manuscript Title:	Title: Investigative Algorithms for Disorders Affecting plasma proteins with a focus on albumin and the calculated globulin fraction. A Narrative Review
Manuscript Number (if known):	Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

			ne all entities with whom you have this tionship or indicate none (add rows as ded)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	ng of the work
1	the present manuscript (e.g.,		None	
	funding, provision of			Click the tab key to add additional rows.
r a P C	study materials, medical writing, article processing charges, etc.) No time limit for this item.			~
	_		Time frame: past 36 mor	iths
2	Grants or contracts from any entity (if not indicated in	X	None	
	item #1 above).			

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	☑ None	
4	Consulting fees	☑ None □ □	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☑ None □ □ □ □	
6	Payment for expert testimony	☑ None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	☑ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	☑ None □ □	
10	Leadership or fiduciary role in	🗷 None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	other board, society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☑ None	
13	Other financial or non-financial interests	☑ None □ □ □ □	
Please place an "X" next to the following statement to indicate your agreement:			

ICMJE DISCLOSURE FORM

Date:	2/28/2023
Your Name:	Alexa R Shipman
Manuscript Title:	Investigative Algorithms for Disorders Affecting plasma proteins with a focus on albumin and the calculated globulin fraction. A Narrative Review
Manuscript Number (if known):	Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

			ne all entities with whom you have this tionship or indicate none (add rows as ded)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planni	ng of the work
1	1 All support for the present manuscript (e.g., funding,		None	
	provision of			Click the tab key to add additional rows.
r a F C	study materials, medical writing, article processing charges, etc.) No time limit for this item.			
			Time frame: past 36 mor	oths
2	Grants or contracts from any entity (if not	X	None	
	indicated in item #1 above).			

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None None	
4	Consulting fees	☑ None □ □ □ □ □ □	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	 None I receive an honoraria for being editor in chief of Clinical and Experimental Dermatology 	The payment is made to me annually
6	Payment for expert testimony	☑ None	
7	Support for attending meetings and/or travel	☑ None	
8	Patents planned, issued or pending	☑ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in	🗶 None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	other board, society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☑ None □ □ □ □	
13	Other financial or non-financial interests	☑ None □ □ □ □	
Ple:		next to the following statement to indicate your e answered every question and have not altered th	

ICMJE DISCLOSURE FORM

Date:	2/27/2023
Your Name:	Kate Shipman
Manuscript Title:	Investigative Algorithms for Disorders Affecting plasma proteins with a focus on albumin and the calculated globulin fraction. A Narrative Review
Manuscript Number (if known):	Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		rela	ne all entities with whom you have this tionship or indicate none (add rows as ded)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planni	ng of the work
1	All support for the present	X	None	
	manuscript (e.g., funding,			
	provision of			
	study materials,			Click the tab key to add additional rows.
	medical writing, article processing charges, etc.) No time limit for this item.			
			Time frame: past 36 mor	iths
2	contracts from	X	None	
	any entity (if not indicated in			
	item #1 above).			

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	☑ None	
4	Consulting fees	☑ None □ □ □ □ □ □	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	□ None Amgen Daiichi Sankyo	Amarin Novartis
6	Payment for expert testimony	☑ None	
7	Support for attending meetings and/or travel	□ None Amgen	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	☑ None □ □ □ □	
10	Leadership or fiduciary role in	□ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	other board, society, committee or advocacy group, paid or unpaid	Deputy managing editor of Lab Tests Online (UK)	
11	Stock or stock options	☑ None □ □ □ □	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☑ None	
13	Other financial or non-financial interests	☑ None □ □ □ □	
Please place an "X" next to the following statement to indicate your agreement:			